Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board

JUPITER, Fla., Feb. 4, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded worldwide biotechnology business creating products to lessen the stress of ischemia-reperfusion damage in tissue grafting, organ transplant, and other surgical indications, introduced these days that it has named veteran small business government Julie Kampf as an Unbiased Member of its Board of Administrators.

“Ms. Kampf will present a must have advice as an Impartial Member of Marizyme’s Board of Administrators as the corporation accelerates scientific and professional advancement and places a concurrent emphasis on profits technology in the calendar year forward,” said Dr. Neil J. Campbell, Marizyme’s CEO, President and Board Member. “She has a stellar standing as a world-wide small business government and considered chief in the everyday living science arena.”

Ms. Kampf has much more than 30 years’ expertise as a world company executive and thought leader on talent and range in the life science industries and on not-for-gain Boards. She is presently CEO of JBK Associates International, a total-company government talent solutions firm, with a specialty in everyday living sciences, which she established in 2003.  Prior to founding JBK and going into the daily life science sector, Ms. Kampf held positions of raising obligation that focused on solution improvement, marketing, product sales and organizational improvement.

Ms. Kampf has significant not-for-gain board and advisory committee knowledge, is deeply fully commited to maximizing the careers and effectively-staying of other girls and has received quite a few awards. She was identified as one of New Jersey’s Very best 50 Women in Organization, an Enterprising Lady of The Calendar year, an Ernst & Youthful Entrepreneurial Winning Female and a Brava Sensible CEO Winner. In 2013 and 2009, Ms. Kampf was identified as 1 of PharmaVoice’s 100 most inspiring men and women in the lifetime science sector.

Ms. Kampf gained a BA in Political Science from the University of Rhode Island exactly where she minored in Marketing.

Ms. Kampf commented, “I am excited to be part of Marizyme’s board and to help the firm as it builds its promising suite of therapies that deal with unmet needs in diseases with higher mortality and charges.”

About Marizyme, Inc.
Marizyme is an integrated existence sciences firm focused to the acquisition, development and commercialization of therapies that reduce mortality and expenses in the acute care house. The Firm’s flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial problems and leads to improved medical outcomes by cutting down the incidence of complications linked with vein graft failure in bypass surgical procedure. DuraGraft boosts coronary artery bypass grafting (CABG) surgical outcomes by considerably cutting down big adverse cardiac activities this sort of as repeat revascularization and myocardial infarction. DuraGraft is accredited for use in the EU and several Asian countries but is not nevertheless accredited for use in the U.S. Marizyme is also centered on the progress and advertising and marketing of merchandise centered on its clinically tested and formerly patented protease-centered therapeutic Krillase® platform. Krillase is not authorised for use in the U.S. For extra facts about Marizyme, take a look at www.marizyme.com.

Forward-Hunting Statements
This press launch may possibly contain particular ahead-looking statements, like those relating to Marizyme’s products development, scientific and regulatory timelines, current market option, competitive placement, attainable or assumed long run benefits of operations, enterprise approaches, likely expansion alternatives and other statements that are predictive in nature. The Firm has created each individual reasonable effort to be certain the data and assumptions on which these statements are primarily based are present, sensible, and complete. However, a wide range of aspects, numerous of which are past the Firm’s command, have an effect on the Company’s functions, overall performance, enterprise method and final results and there can be no assurances that the Company’s precise results will not vary materially from those indicated herein. Further written and oral forward-wanting statements may well be manufactured by the Enterprise from time to time. Ahead-wanting statements may well be determined utilizing ahead-wanting expressions, like, but not confined to, “be expecting,” “anticipate,” “intend,” “approach,” “imagine,” “estimate,” “opportunity,” “predict,” “task,” “must,” “would” and similar expressions and the negatives of those people conditions. These statements relate to potential activities or our economical overall performance and contain recognized and unidentified hazards, which includes those people dangers established forth in the Firm’s danger factor disclosure in the reviews that Marizyme files with the Securities and Trade Commission (SEC File No. 000-53223), uncertainties, and other factors which may well result in precise effects, efficiency or achievements to be materially various from any future final results, effectiveness or achievements expressed or implied by the forward-looking statements. Possible investors are cautioned not to place undue reliance on this sort of ahead-searching statements, which converse only as of the date of this press launch. The Firm undertakes no obligation to publicly update any ahead-hunting assertion, no matter whether as a outcome of new information, upcoming functions or otherwise.

CONTACT 
Tiberend Strategic Advisors, Inc. 
Investors 
Miriam Weber Miller 
212-375-2694 
[email protected]

Media
Ingrid Mezo
646-604-5150
[email protected]

Resource Marizyme, Inc.

Connected Back links

https://marizyme.com/